Keep it moooving $MLAB
181
Market rallies on a shit jobs report. Quite funny how it all actually functions. I watched rate hike odds in prediction markets crash from over 80% down to 14% with the blink of an eye. Wild times indeed
1
4
170
$OCC she has legs without me now, though I made my gains on the initial move from under $10 months ago. Feels like someone knows something re Lightera/Furukawa… buying up what they can this past week or so 🧐
1
165
By the same token, $TLSA worth a look for a tiny allocation on a quick trade. Stock will explode if trial results come out positive, though dilution is subsequently seemingly imminent.
$VKTX is worth diversifying in portfolios for a small allocation in the low to mid $20’s (should it get there). Some risk, but exceptional potential reward in a booming obesity market. Emphasis on smaller allocation here
1
255
There she goes
You’re gonna want to get you some 🐧 before next week, ideally under $55! Another trip to the $40’s before then would be a cherry on top. $PENG
I’ll reiterate the ~$117/share convertible note offering at a 50% premium to the $78/share it was trading at following its last explosive ER. This coincided with management acquiring capped calls to circumvent such eventual dilution, a maneuver I would liken to Digital Ocean’s convertible note situation when it was trading in the $30’s just last year. This $750 million offering was oversubscribed by institutions as well, clashing with Tim from Barclays’ petty downgrades. I’ll follow the money and assume he just wants better prices for his institutional client base. Hoping the integrated memory unit can withstand ever rising hardware inflation, in the quest for a blended gross margin base crossing that 30% threshold.
I will be a buyer at $45-55 for the long haul.
2
107
You’re gonna want to get you some 🐧 before next week, ideally under $55! Another trip to the $40’s before then would be a cherry on top. $PENG
I’ll reiterate the ~$117/share convertible note offering at a 50% premium to the $78/share it was trading at following its last explosive ER. This coincided with management acquiring capped calls to circumvent such eventual dilution, a maneuver I would liken to Digital Ocean’s convertible note situation when it was trading in the $30’s just last year. This $750 million offering was oversubscribed by institutions as well, clashing with Tim from Barclays’ petty downgrades. I’ll follow the money and assume he just wants better prices for his institutional client base. Hoping the integrated memory unit can withstand ever rising hardware inflation, in the quest for a blended gross margin base crossing that 30% threshold.
I will be a buyer at $45-55 for the long haul.
2
449
Remind me never to question the 🐐 again. $NTRA
I’m still trying to comprehend why Stanley Druckenmiller would wholly sell out of everything AI related while pivoting to increase/average up his top position in $NTRA. In a market wide sell off, you’d expect healthcare to catch a bid, but this is just as big an “overvalued” spec as they come, and would likely sell off along with anything else pricing in perfect execution through the 2030’s. I’m sure he’s absolutely loaded up on puts since last month, but nonetheless, a semi baffling move from the goated investor at least from my vantage point
1
269
$VKTX is worth diversifying in portfolios for a small allocation in the low to mid $20’s (should it get there). Some risk, but exceptional potential reward in a booming obesity market. Emphasis on smaller allocation here
1
580
Added to $NLST under $5
Sold out of $PENG again
$OSS waiting on $8’s to add more should we get there
$SILC waiting on $35 to add now should we get there; this one got quite overhyped on this platform in previous weeks coupled with exorbitant insider selling
$CRSR seeking under $11 once more
$OCC ER next week, may play it depending on how the market opens on Tuesday
$ZVRA will add a bunch more if we see under $12 again
$IOVA as well if we see under $8 again
Overall brutal -2-3% day thanks in large part to $HPE; should be $60+ but I guess I’ll play the waiting game as institutions hawk for better entry levels.
1
5
1,072
Update: Sold $ZVRA above $12 couple weeks back, would consider getting back in at $8-9. Despite its solid fundamentals, there’s just too much risk involved for my liking at this juncture.
286
$IOVA is a behemoth!!
$IOVA A retrace to $6-7 feels in the cards this interim, where you’ll want to buy and hold for a year+. $20-30 on the eventual horizon … especially if the phase 2 IOV-LUN-202 trial evaluating lifileucel in advanced non-small cell lung cancer (NSCLC) is granted expedited approval. I have trimmed my position in anticipation of a correction.
Meanwhile $STIM is likely to double from here, although I trimmed some profits above $3 this week.
Then $ZVRA is too relatively cheap to ignore at these price levels, although it may dip back to $9-10 before my expectation of $16-20/share, and then some.
$ZTS is cheap and why not follow the crony king Ro Khanna in his insider trading schemes?
1
266
$FTEK on a heater
4
580
$RELL at $15-16 again is a supreme long term buy. Perhaps the macro situation at hand pushes it down to $14 range but that would be a nice DCA opportunity.
3
397